Cargando...
Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress
The ability of the Cav1 channel inhibitor isradipine to slow the loss of substantia nigra pars compacta (SNc) dopaminergic (DA) neurons and the progression of Parkinson’s disease (PD) is being tested in a phase 3 human clinical trial. But it is unclear whether and how chronic isradipine treatment wi...
Gardado en:
| Publicado en: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Clinical Investigation
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983329/ https://ncbi.nlm.nih.gov/pubmed/29708514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI95898 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|